desmoteplase
Lundbeck appoints Tarek Samad as EVP, Head of Research & Development
Samad previously held senior research leadership positions at Immunitas Therapeutics, Sanofi and Pfizer
Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment
The rare neurodegenerative disorder has no cure and no approved treatments
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
TNKase is the first stroke medicine to be approved by the regulator in almost three decades
MHRA launches second phase of genetic biobank for stroke prevention medicines
The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
NICE recommends two AI-powered software tools for stroke diagnosis in NHS
Brainomix's e-Stroke and Ischemaview’s RapidAI were reported by the health technology assessment agency to improve access to treatment for stroke patients
NICE recommends wider use of statins to cut risk of heart attack and stroke
The guidance comes after new evidence was considered on the side effects and safety of statins
NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales
In England, more than six million people live with cardiovascular disease, costing the NHS around £7.4bn per year
AstraZeneca’s Brilinta reduces rate of secondary stroke
Drug helps to prevent rate of stroke and death by 17%
Lundbeck drops Parkinson’s drug acquired in €905m deal
Disappointment after drug failed in a mid-stage clinical trial
Lundbeck gets US approval for migraine drug at heart of Alder takeover
US regulator clears CGRP inhibitor under Vyepti trade name
AZ says Brilinta hits the mark in new stroke trial
Drug met primary endpoint in phase 3 THALES trial
